Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.
Satyendra Chandra TripathiJohannes F FahrmannJody V VykoukalJennifer B DennisonSamir M HanashPublished in: Cancer reports (Hoboken, N.J.) (2018)
Use of small molecule inhibitors aimed at exploiting tumor metabolic vulnerabilities continues to be an active area of research. Identifying metabolic dependencies specific to cancer cells and/or constituents of the tumor microenvironment is a viable area of therapeutic intervention that holds considerable clinical potential.